CXCL5 and familial pancreatic carcinoma: Besides NSCLC, several previous studies showed that increased expression level of CXCL5 was an adverse prognosis biomarker in pancreatic cancer, hepatocellular carcinoma, and bladder cancer.38, 39, 40